Transcept Hopes To Sleep Well Thanks To Insomnia Pill Deal With Purdue Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
The drug maker hopes to market the first medication for people who wake in the middle of the night.
You may also be interested in...
Transcept/Purdue’s Intermezzo Gets $29 Million Re-launch
The companies will bulk up their sales force and begin a direct-to-consumer campaign in an effort to boost sales for their sleep aid, which has gotten off to a slow start since its launch in April.
Bright-Eyed And Bushy Tailed: Purdue Launches Intermezzo
Purdue Pharma launched Transcept Pharmaceutical’s Intermezzo, a low-dose sublingual tablet version of the generic sleep aid zolpidem, for middle-of-the-night awakenings April 5. Priced at a wholesale acquisition cost of $6.45 per tablet, the drug could face an uphill commercial road competing against generics.
Transcept Sees Road To Intermezzo Approval Without More Driving Studies
The company says FDA "generally agreed" with a proposal for dosing reductions and labeling changes for the middle-of-the-night insomnia drug, which has received two "complete response" letters.